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Background
Chronic thromboembolic pulmonary hypertension after pulmonary embolism is associated
with high morbidity and mortality. Understanding the incidence of chronic thromboembolic
pulmonary hypertension after pulmonary embolism is important for evaluating the need for
screening but is also a subject of debate because of different inclusion criteria among previous
studies. We determined the incidence of chronic thromboembolic pulmonary hypertension
after acute pulmonary embolism and the utility of a screening program for this disease.
Design and Methods
We conducted a cohort screening study in an unselected series of consecutive patients (n=866)
diagnosed with acute pulmonary embolism between January 2001 and July 2007. All patients
who had not been previously diagnosed with pulmonary hypertension (PH) and had survived
until study inclusion were invited for echocardiography. Patients with echocardiographic sus-
picion of PH underwent complete work-up for chronic thromboembolic pulmonary hyper-
tension, including ventilation-perfusion scintigraphy and right heart catheterization. 
Results
After an average follow-up of 34 months of all 866 patients, PH was diagnosed in 19 patients
by routine clinical care and in 10 by our screening program; 4 patients had chronic thromboem-
bolic pulmonary hypertension, all diagnosed by routine clinical care. The cumulative incidence
of chronic thromboembolic pulmonary hypertension after all cause pulmonary embolism was
0.57% (95% confidence interval [CI] 0.02-1.2%) and after unprovoked pulmonary embolism
1.5% (95% CI 0.08-3.1%). 
Conclusions
Because of the low incidence of chronic thromboembolic pulmonary hypertension after pul-
monary embolism and the very low yield of the echocardiography based screening program,
wide scale implementation of prolonged follow-up including echocardiography of all patients
with pulmonary embolism to detect chronic thromboembolic pulmonary hypertension does
not seem to be warranted.
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Introduction
Chronic thromboembolic pulmonary hypertension
(CTEPH) is a life-threatening condition characterized by
intraluminal thrombus organization and fibrous stenosis or
complete obliteration of the pulmonary arteries.1 CTEPH is
commonly seen as a long-term sequel of acute pulmonary
embolism (PE), although the pathogenesis of impaired
clearance of acute thrombi and the resulting vascular
remodeling is unknown, and there is no history of symp-
tomatic venous thromboembolism (VTE) in 31–42% of the
patients diagnosed with CTEPH.1-3
The incidence of CTEPH has been reported to be
between 0.1% and 8.8% in patients after acute PE.1,4-7 This
wide range can be explained by important differences in
the inclusion and diagnostic criteria between these previ-
ous studies: selection of patients was often based on the
etiology of the acute PE, patients with further comorbid
conditions associated with pulmonary hypertension were
frequently excluded and the diagnosis of CTEPH was not
always confirmed by right heart catheterization.1,4-7
Since CTEPH is a very serious but potentially treatable
disease, the exact incidence of CTEPH in the clinical course
of acute PE is of particular interest. High frequencies of
3.8% to 8.8%4,6 would suggest the need for prolonged fol-
low-up after discontinuation of anticoagulant therapy
including specific screening programs for CTEPH by
echocardiography, whereas lower frequencies would not.
The purpose of this study was to evaluate the efficacy of a
screening program for CTEPH in patients after acute PE.
This evaluation was based on the overall incidence of
CTEPH and the additional utility of this screening program
on top of standard clinical care. Accordingly, we performed
a prospective cohort screening study evaluating the occur-
rence of CTEPH in an unselected large series of patients
diagnosed with acute PE. 
Design and Methods
Patients
Consecutive patients diagnosed with an episode of acute PE in
the period between January 1st 2001 and July 1st 2007 of an aca-
demic institute (Leiden University Medical Center, Leiden, the
Netherlands) and affiliated teaching hospital (Medical Center
Haaglanden, The Hague, the Netherlands) were eligible for study
inclusion, irrespective of age, medical history or comorbid condi-
tions. Neither of these 2 hospitals serves as a tertiary referral cen-
ter for CTEPH. All patients diagnosed and treated for acute PE are
registered in a database by physicians of all clinical specialities of
both hospitals. For the purpose of this study, we crosschecked this
database with data from the radiology department to ensure no
patients were missing. The diagnosis of acute PE was verified for
all registered patients according to predefined criteria which were
intraluminal filling defects on pulmonary angiography or comput-
ed-tomography pulmonary-angiography (CTPA), high probability
ventilation perfusion scintigraphy (VQ-scan) or intermediate
probability VQ-scan in combination with objectively diagnosed
deep venous thrombosis (DVT).8 All patients fulfilling these crite-
ria were included in this analysis. Unprovoked PE was defined as
PE occurring in the absence of the following risk factors: active
malignancy, immobility for more than three days or recent long
flight (over six hours), recent surgery or fracture of extremity,
pregnancy or peri-partum period, hormone replacement therapy
and use of oral contraception. Patients were initially treated with
at least five days of either unfractioned heparin, aiming at a 1.5 to
2.5 prolongation of the activated partial thromboplastin time, or
weight based therapeutic doses of LMWH, followed by vitamin K
antagonists for a period of at least six months with a target inter-
national normalized ratio (INR) of 2.0 to 3.0.9 In patients with
severe acute PE, anticoagulant treatment was preceded by admin-
istration of thrombolytic drugs, thrombosuction or surgical
embolectomy according to the judgment of the attending clini-
cian. Clinical follow-up and treatment monitoring after hospital
discharge were performed in the local pulmonary, internal or vas-
cular medicine outpatient clinic as well as in the anticoagulation
clinic.
Outcome
Primary outcomes of this study were the incidence of CTEPH
and the effectiveness of our screening program. Criteria for the
diagnosis of CTEPH were mean pulmonary artery pressures
assessed by right heart catheterization exceeding 25 mmHg and
normal pulmonary capillary wedge pressure in combination with
an abnormal perfusion scintigram and signs for distal or central
CTEPH on conventional pulmonary angiography.10,11 CTEPH was
considered excluded in case of a normal perfusion scintigram.10,11
Procedures
The original admission and outpatient medical charts of all
patients diagnosed with acute PE in the registration period were
systematically reviewed using predefined criteria. Only patients
with geographical inaccessibility (living outside the Netherlands)
precluding follow-up were excluded from the study. Data regard-
ing diagnostic management, etiology, treatment and documented
clinical course of the acute PE at registration as well as recurrent
episodes, and established diagnosis of pulmonary hypertension
were assembled. Only recurrent events that were objectively con-
firmed according to our predefined criteria were accounted for.
For all eligible patients who had died before study inclusion (July
2007), time and cause of death were extracted from the autopsy
report or verified with the treating physician or general practition-
er. All surviving patients prior to diagnosis of pulmonary hyper-
tension were interviewed by telephone to complete the data
derived form their medical charts, to obtain information regarding
the presence of clinical symptoms suggestive of pulmonary
hypertension and, if applicable, the results of recent echocardiog-
raphy. In addition, information on known risk factors for CTEPH
was noted down for patients who had been previously diagnosed
with CTEPH: these include large central emboli, unprovoked
VTE, splenectomy, presence of lupus anticoagulant or antiphos-
pholipid antibodies, chronic inflammatory conditions and ven-
triculo-atrial shunts.12 Furthermore, all surviving patients were
invited for a single visit to our vascular medicine outpatient clinic
for pulmonary hypertension screening by echocardiography. This
visit was scheduled between July 1st 2007 and January 1st 2009 and
planned at least one year after the index event, or one year after a
recurrent thrombo-embolic episode, to rule out the initial effect of
acute PE. All patients who responded to our invitation underwent
physical examination and standardized transthoracic echocardio-
graphy performed by an experienced technician. This echocardio-
graphy was reviewed by an independent expert cardiologist,
without knowledge of the patient’s medical condition.
Echocardiographic criteria for suspected pulmonary hypertension
were one or more of the following: 1) maximal tricuspid regurgi-
tation velocity over 2.8 m/s; 2) estimated systolic pulmonary
artery pressureof 35 mmHg or over (maximal pressure gradient
across the tricuspid valve calculated by the modified Bernoulli
equation plus the estimated right atrium pressure); 3) estimated
mean pulmonary artery pressure of 25 mmHg or over (estimated
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systolic pressure plus 2 times end-diastolic pressure as estimated
by pulmonary regurgitation end-diastolic velocity divided by 3; 4)
borderline value of criterion 1 or 2 in combination with a right
ventricular TEI index over 0.36 (isovolumic contraction time plus
isovolumic relaxation time divided by ejection time); 5) secondary
changes associated with pulmonary hypertension, e.g. systolic
septal flattening, right ventricular hypertrophy or W-pattern in the
right ventricular outflow curve; 6) AcT (acceleration time ) under
120 or AcT/RVET (right ventricular ejection time) under 0.40.11,13,14
All patients who met one or more of these 6 criteria were suspect-
ed of having pulmonary hypertension and underwent further
standardized work-up including perfusion lung scintigraphy and
right heart catheterization for pressure measurements. The final
diagnosis was assessed by an independent expert panel according
to our predefined criteria. This study was approved by the
Institutional Review Board of both participating hospitals and all
patients provided written informed consent.
Statistical analysis
Patients were categorized in 4 sub-groups according to their
medical history of single or recurrent and provoked or unpro-
voked PE. The cumulative incidence of CTEPH after acute PE for
all 4 study groups was calculated by the Kaplan-Meier life table
method. In addition, we calculated the incidence rates of CTEPH.
The number of patient years (py) for both analyses was calculat-
ed from the date of the index event until diagnosis of CTEPH was
established or ruled out or else until death had occurred, whichev-
er came first. Finally, for a more conservative estimation of the
incidence of CTEPH after acute PE, we performed a second analy-
sis including only the patients in whom objective testing for
CTEPH was performed. SPSS version 14.02 (SPSS Inc, Chicago, IL,
USA) was used for all analyses.
Results
Patients
In 877 patients the diagnosis of acute PE had been estab-
lished between January 1st 2001 and July 1st 2007. Eleven
patients were excluded because of geographical inaccessi-
bility, leaving 866 patients who were included in the study.
General characteristics of these patients are shown in Table
1: mean age at registration was 56 years, 410 (47%) were
males and 308 patients (36%) had had an unprovoked
episode of PE. More than 90% of patients were initially
treated with either unfractionated heparin or LMWH
alone. A small number of patients additionally received
thrombolytic therapy, had a vena cava filter inserted or had
surgical embolectomy performed (Table 1). The average
follow-up period was 2.8 years. 
Chart review
After reviewing the medical charts of all patients, 19
cases of previously diagnosed pulmonary hypertension
were identified (Figure 1) of whom 4 had CTEPH. During
the study period, 259 patients died, 75 (8.7%) as a direct
result of acute (recurrent) PE, 88 (10%) of malignant dis-
ease and 96 (11%) from other conditions. Of these 259
patients, 185 (71%) had died within the first year after the
acute PE, 216 (83%) within two years, 238 (92%) within
three years and 247 (95%) within four years. In 69 patients,
autopsy reports or echocardiography performed before the
patient’s death ruled out the presence of pulmonary hyper-
tension. Furthermore, pulmonary hypertension was not
adjudicated as cause of death in any of these patients.
Therefore, and in accordance with criteria from previous
studies,4-7 we assumed that none of these patients had
developed CTEPH.
The remaining 588 patients were invited for our screen-
ing program. We were able to complete this program in
402 (68%) of them. Of these patients, 170 had symptoms
suggestive of CTEPH. Echocardiographic criteria for sus-
pected pulmonary hypertension were met by 25 patients.
After further clinical work-up and right heart catheteriza-
tion, pulmonary hypertension was diagnosed in 10 of
these patients. 
From the 186 patients who did not respond to our invi-
tation, 38 had undergone echocardiography for clinical rea-
sons other than our screening study. None of these patients
was diagnosed with pulmonary hypertension after evalu-
ating these echoes for our predefined criteria for suspected
pulmonary hypertension. Objective testing for pulmonary
hypertension was not performed in the remaining 148 sur-
viving patients. Of these, 97 declared themselves to be in
excellent health without any physical complaints and to
have no time to be involved in any clinical trials. The final
51 patients were unable to visit our hospital due to old age
or comorbid conditions. Most of these patients were over
the age of 80 years and suffered from severe cancer. Of
these latter 51 patients, 10 reported exertional dyspnea that
was reasonably explained by previously diagnosed car-
diopulmonary diseases, i.e. chronic obstructive pulmonary
disease (COPD), systolic left-sided heart failure, pul-
monary cancer, severe anemia or a combination of these
conditions. Since none of these patients had unexplained
dyspnea,4-6 we assumed that CTEPH was not present in
these patients for the purpose of the incidence calculation.
Incidence of chronic thromboembolic pulmonary 
hypertension
Upon study inclusion, 19 patients with a history of PE
had already been diagnosed with pulmonary hypertension
of various causes. Among these, 4 had been diagnosed
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Table 1. Characteristics of included patients. 
Study patients (n=866)
Age at registration event (years±SD) 56±19
Age at first PE (years±SD) 55±18
Male sex (n, %) 410 (47)
Unprovoked PE (n, %) 308 (36)
Initial treatment first PE
Low molecular/unfractioned heparin (n, %) 808 (93)
Thrombolysis (n, %) 38 (4.4)
Surgery, VCF or both (n, %) 20 (2.3)
COPD (n, %) 83 (9.6)
Left sided heart failure (n, %) 42 (4.8)
Mortality§ (n, %) 259 (30)
PE related (n, %) 67 (7.7)
Malignancy related (n, %) 110 (13)
Other (n, %) 82 (9.4)
Number of patients years‡ 2427
PE: pulmonary embolism, VT=venous thrombosis, SD= standard deviation, n=number,
VCF=vena cava filter; ‡number of years from registration date until diagnosis of CTEPH
was established or ruled out, or until death had occurred, §mortality between registra-
tion date and July 1st 2007 (start cross sectional cohort study). 
with CTEPH by routine clinical care and CTEPH was ruled
out by perfusion scintigraphy or pulmonary angiography
in the remaining 15 patients. Our screening program iden-
tified an additional 10 patients with pulmonary hyperten-
sion, but distal or central CTEPH was ruled out in all of
these patients after normal perfusion scintigraphy or pul-
monary angiography. All 4 patients with CTEPH returned
to their physician within two years after their first acute PE
because of typical symptoms of CTEPH, including exer-
tional dyspnea (Table 2). None of them was found to have
additional risk factors for CTEPH or other comorbidities
causing pulmonary hypertension. The diagnoses were con-
firmed by right heart catheterization and measurement of
pulmonary artery pressure. Mean time to diagnosis was
260 days. The cumulative incidence of CTEPH in our
cohort was 0.57% (4/866, 95% CI 0.02-1.2%) in the over-
all population, 1.5% (4/308, 95% CI 0.08-3.1%) in the
patients with unprovoked PE and 0.0% (0/558) in the
patients with provoked PE (Table 3 and Figure 2). Incidence
rate of CTEPH was 0.16/100 py (95% CI 0.04-0.42/100 py)
for the overall population, 0.44/100 py (95% CI 0.12-
1.1/100 py) for patients with unprovoked PE and 0.0/100
py (95% CI 0.0-0.24/100 py) for patients with provoked PE
(Table 3). There was no difference in incidences following
a single event or recurrent disease between the study
groups (Table 3). Lastly, to provide a more conservative
estimation of the CTEPH incidence after acute PE, we cal-
culated the separate incidence solely for the patients in
whom CTEPH was objectively ruled out or established
(incidence 0.80%, 95% CI 0.01-1.9).
Follow-up of patients with chronic thromboembolic 
pulmonary hypertension
Because of distal pulmonary artery involvement, only
one of the 4 patients with CTEPH was considered suitable
for pulmonary endarterectomy. However, this patient
refused surgery for personal reasons and was treated with
the oral dual endothelin receptor antagonist bosentan.15
Two additional patients were treated with bosentan of
whom one developed severe elevation of transaminases
and this treatment was consequently stopped. The final
patient did not receive treatment because of the benign
clinical presentation of CTEPH (NYHA Class II, satisfacto-
ry exercise tolerance without severe desaturation during
maximal exercise). At the moment of drafting this paper
(April 1st 2009) and after a mean follow-up of 43 months
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Table 2. Characteristics of patients with chronic thromboembolic pulmonary hypertension. 
Sex Age at Recurrent Risk factor Localization Thrombolysis, Additional Time from first Mean PAP at NYHA
first PE PE first PE first PE VCF or surgery risk factors PE to diagnosis diagnosis CTEPH classification at
(years) for first PE for CTEPH§ CTEPH (days) (mmHg) diagnosis
CTEPH
1 female 70 Yes Unprovoked segmental No none 118 48 II
2 male 68 No Unprovoked central No none 298 50 III
3 female 59 No Unprovoked central No none 466 48 III
4 female 65 No Unprovoked segmental No none 157 49 III
CTEPH=chronic thromboembolic pulmonary hypertension, PE=pulmonary embolism, VCF=vena cava filter, PH=pulmonary hypertension, NYHA=New York Heart Association,
PAP=pulmonary artery pressure; §additional risk factors for CTEPH to central PE and idiopathic PE, i.e. splenectomy, lupus anticoagulant or antiphospholipid antibodies, chronic
inflammatory conditions and ventriculo-atrial shunts.12
Figure 1. Flow chart of the cohort study. 
PE=pulmonary embolism,
PH=pulmonary hyperten-
sion, CTEPH=chronic
thromboembolic pul-
monary hypertension; ‡in
all 10 patients (100%)
with dyspnea, previously
diagnosed cardiopul-
monary disease reason-
ably explained the dysp-
nea, i.e. chronic obstructive
pulmonary disease, sys-
tolic or diastolic heart fail-
ure, pulmonary cancer,
severe anemia or a combi-
nation of these conditions,
was reported.
after diagnosis of CTEPH, the clinical condition of all 4
patients was stable.
Efficacy of the screening program
Ten patients with pulmonary hypertension were identi-
fied by the screening program in the 402 patients with a
history of acute PE but without established pulmonary
hypertension 2.8 years after the acute thromboembolic
event. Pulmonary angiography did not reveal CTEPH in
these 10 patients: the pulmonary hypertension was caused
by left sided heart disease in 5 patients and by COPD in
the remaining 5 patients. All patients with CTEPH from
our total study population were previously diagnosed by
routine clinical practice.
Discussion
This study has two main findings. First, we observed a
0.57% incidence of CTEPH after acute PE in an unselected
large patient series. Second, the yield of a standard screen-
ing program to detect CTEPH in patients after acute PE is
low, since additional cases of CTEPH to cases identified by
routine clinical care were not detected in our study popu-
lation.
Understanding of the incidence of CTEPH is important
to guide the screening and diagnostic strategy in patients
after acute PE. The incidence of CTEPH we observed chal-
lenges other studies reporting higher incidences ranging
from 3.8% to 8.8%.4-7 There are several reasons for these
discrepancies. These previous studies included selected
patient cohorts, e.g. excluding patients with transient or
permanent risk factors for PE5 and excluding patients with
other conditions associated with pulmonary hyperten-
sion.4-6 In addition, the diagnosis of CTEPH was partly
based on results from echocardiography alone without
confirmation by right heart catheterization.6 In the study
by Pengo et al. an incidence of 3.8% after two years was
reported, which is considerably higher than the incidence
observed in our population.4 The main differences between
the two studies were the inclusion criteria: whereas we
only excluded patients who were geographically inaccessi-
ble for follow-up, Pengo also excluded all patients with
other diseases that could have caused non-thromboembol-
ic pulmonary hypertension (e.g. severe emphysema) or had
preexisting exertional dyspnea. Although given our study
design we were unable to estimate precisely the prevalence
of those latter patients in our cohort, they provide a consid-
erable contribution to our sample size. The selection crite-
ria applied by Pengo may have influenced their results,
leading to a higher incidence of CTEPH. However, the
duration to diagnosis (within two years after diagnosis of
PE) was comparable between the 2 studies.
We consider our results to be representative for several
reasons. First, we included all patients who presented to
the participating hospitals, independently of etiology or
severity of the acute PE or presence of comorbid condi-
tions. Our study comprised 3 times the number of previous
reports and only 11 patients (1.3%) were excluded.
Second, we used very sensitive echocardiographic criteria
for establishing the suspicion of pulmonary hypertension
and confirmed all cases of CTEPH with heart catheteriza-
tion.11,13,14 Third, the incidence of CTEPH in patients with
unprovoked PE in our study was 1.5%. This is in accor-
dance with or within the lower limit of the confidence
interval of the incidences described in studies focusing
solely on patients with unprovoked PE.4,5
It could be reasoned that our estimation of 0.57% repre-
sents an underestimation of the incidence of CTEPH since
objective testing to confirm or reject this diagnosis was not
performed in the whole study population. However, this
same issue can be applied to all previous reports on this
subject. The vast majority of the non-survivors in our
study died within one year after the PE was diagnosed, and
a reasonable alternative cause of death was reported in all
of them. Furthermore, all cases of CTEPH presented with
symptoms of cardiopulmonary impairment. Hence, it is
unlikely that we missed cases of CTEPH in the asympto-
matic patients who were not able to visit our outpatient
clinic or in the patients who had died. Also, plausible alter-
native diagnoses for dyspnea were confirmed in all 10
patients who reported exertional dyspnea but did not visit
our outpatient clinic. We nonetheless have provided an
additional, more conservative estimation of the CTEPH
incidence by calculating this incidence in a selected patient
population who all underwent objective testing for CTEPH
F.A. Klok et al.
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Table 3. Cumulative incidence by the Kaplan-Meier life table method, and inci-
dence rates of CTEPH in the study population.
Population Cumulative Incidence 
incidence rate
n CTEPH/n overal l% 95%CI n/100 py 95%CI
Overall population 4/866 0.57 0.02-1.2 0.16 0.04-0.42
Single event 3/671 0.59 0.02-1.3 0.16 0.03-0.48
Recurrent events 1/195 0.53 0.01-1.6 0.17 0.004-0.93
Idiopathic PE 4/308 1.5 0.08-3.1 0.44 0.12-1.1
Single event 3/220 1.7 0.05-3.7 0.47 0.10-1.4
Recurrent events 1/88 1.2 0.01-3.6 0.37 0.01-2.1
Provoked PE 0/558 0.0 - 0.0 0.0-0.24
Single event 0/451 0.0 - 0.0 0.0-0.31
Recurrent events 0/107 0.0 - 0.0 0.0-1.1
n: number, CTEPH: chronic thromboembolic pulmonary hypertension, CI: confidence interval, PE:
pulmonary embolism.
Figure 2. Cumulative incidence of chronic thromboembolic pul-
monary hypertension.
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Limitations of our study include the lack of accurate data
on the time from complaints to diagnosis of PE, which is a
hypothetical risk factor for CTEPH, and the different fol-
low-up periods between the study patients, which could
complicate the interpretation of our results. Even so,
patients who completed our screening program underwent
echocardiography at least one full year following the index
acute PE, with a mean follow-up period of 3.7±1.4 years,
which is well over the two year detection frame described
by Pengo et al.4
The mortality as well as the recurrence rates in our
cohort were relatively high. Since we did not apply any
exclusion criteria except for geographical inaccessibility,
patients who would not have been eligible for other stud-
ies because of poor prognosis or other reasons, were in fact
included in the current analysis. Hence, our population
consisted of relatively more patients with serious comor-
bidity explaining the high mortality rate. Also, we includ-
ed patients with a first as well as with recurrent VTE. Some
patients suffered form recurrent VTE during the follow-up
period and were therefore also classified in the recurrence
group, resulting in a relatively high number of patients
with recurrent VTE.
In this study, a cardiopulmonary screening program to
detect CTEPH was evaluated. Although completed by 402
patients, this screening program did not result in any addi-
tional patients being detected with a diagnosis of CTEPH
beside those patients who were identified by routine clin-
ical practice. In combination with the low frequency of
CTEPH, this leads to the conclusion that wide scale imple-
mentation of screening programs for CTEPH after acute PE
is not warranted and echocardiography to rule out or
establish CTEPH should be restricted to patients present-
ing with characteristic symptoms. 
We conclude that CTEPH is a rare complication of acute
PE (incidence 0.57%) and that this diagnosis is more fre-
quent in patients with unprovoked acute PE (incidence
1.5%). CTEPH becomes clinically apparent and is diag-
nosed within the first two years following acute PE. Wide
scale screening for CTEPH after acute PE results in a very
low yield. Although CTEPH occurs infrequently in the clin-
ical course of acute PE, physicians should be aware of this
potentially lethal but treatable disease, especially in those
patients with unprovoked disease and persistent dyspnea.
The direct clinical consequence of our study is that because
of the very low incidence of CTEPH after PE, the imple-
mentation of extensive follow-up programs for the detec-
tion of CTEPH after acute PE seems to be unnecessary.
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